Vaccine Trade Returns? Moderna Working On Hantavirus Shot Sends Shares Higher

Vaccine Trade Returns? Moderna Working On Hantavirus Shot Sends Shares Higher

Moderna is out with timely news that it is working on early-stage research on vaccines targeting hantaviruses. The news comes as a Spanish woman has been hospitalized for a suspected infection, while a hantavirus cluster has ravaged a Dutch-flagged cruise ship, with five confirmed and three suspected cases of hantavirus. Three deaths have been reported so far.

Bloomberg reports that Moderna is collaborating with the U.S. Army Medical Research Institute of Infectious Diseases on hantavirus vaccine research and is also working with Korea University College of Medicine’s Vaccine Innovation Center on a potential vaccine.

“These efforts are early-stage and ongoing and reflect Moderna’s broader responsibility to develop countermeasures against emerging infectious diseases,” Moderna said.

Moderna said its work on hantavirus vaccines began before the cruise ship Hondius reported an outbreak while anchored off the coast of Cape Verde, on the west coast of Africa, last week.

Anais Legand, a technical officer at the World Health Organization (WHO), provided an update earlier today stating that all remaining passengers on the Hondius have left the ship without symptoms.

“They will be asked to take their temperature every single day for 42 days. They will be asked to check every day for other symptoms like feeling unwell or a headache,” Legand said, adding, “They will be provided with someone to contact. If they’re not feeling well, it’s up to the national authorities where people will go next.”

WHO Emergencies Communications Lead Nyka Alexander stated in a livestreamed update earlier that “the risk to the public remains low.”

Nevertheless, the news sent Moderna shares higher around noon. Shares had already been rising after the company reported that its mRNA flu vaccine outperformed in a late-stage study, likely driving early market activity. Shares are up 18%.

President Trump told an ABC News reporter on Thursday that “It’s very much, we hope, under control.” 

Polymarket:

Hantavirus pandemic in 2026?
Yes 9% · No 91%
View full market & trade on Polymarket

It is only a matter of time before other struggling biotech companies announce that they, too, are developing vaccines to prevent the next potential pandemic. This follows the Covid playbook.

Tyler Durden
Fri, 05/08/2026 – 13:05

via ZeroHedge News https://ift.tt/52KjFnH Tyler Durden

Leave a Reply

Your email address will not be published. Required fields are marked *